

Renato Delascio Lopes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8617016/renato-delascio-lopes-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

335
papers

18,604
citations

58
h-index

132
g-index

372
ext. papers

24,309
ext. citations

9
avg, IF

6.49
L-index

#	Paper	IF	Citations
335	Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.. <i>Circulation</i> , 2022 ,	16.7	5
334	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 227-236	27.4	18
333	Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke.. <i>Europace</i> , 2022 ,	3.9	2
332	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 417-427	15.1	2
331	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 20	8.7	3
330	Relationship between ventricular repolarization parameters and the inducibility of ventricular arrhythmias during electrophysiological study in patients with coronary artery disease.. <i>Revista Da Associação Médica Brasileira</i> , 2022 , 68, 61-66	1.4	
329	Risk Scores in Acute Coronary Syndrome: Current Applications and Future Perspectives. <i>International Journal of Cardiovascular Sciences</i> , 2022 , 35, 181-183	0.4	
328	Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease.. <i>European Heart Journal Supplements</i> , 2022 , 24, A19-A31	1.5	0
327	Diagnosis and Treatment of Acute Coronary Syndromes: A Review.. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 662-675	27.4	10
326	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.. <i>Circulation: Cardiovascular Interventions</i> , 2022 , CIRCINTERVENTIONS121011069	6	
325	Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.. <i>Journal of Cardiovascular Translational Research</i> , 2022 , 1	3.3	1
324	Association of Non-Alcoholic Fatty Liver Disease with In-Hospital Outcomes in Primary Heart Failure Hospitalizations with Reduced or Preserved Ejection Fraction.. <i>Current Problems in Cardiology</i> , 2022 , 101199	17.1	0
323	Independence of Clinical Events Committees: A Consensus Statement from Clinical Research Organizations.. <i>American Heart Journal</i> , 2022 , 248, 120-120	4.9	0
322	Associated Factors and Clinical Outcomes in Mechanical Circulatory Support use in Patients Undergoing High Risk On-Pump Cardiac Surgery: Insights from the LEVO-CTS trial.. <i>American Heart Journal</i> , 2022 , 248, 35-35	4.9	
321	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial.. <i>The Lancet Regional Health Americas</i> , 2022 , 11, 100243		0
320	ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor.. <i>American Heart Journal</i> , 2022 , 249, 76-76	4.9	0
319	Disease Modifying Therapies for Transthyretin Amyloid Cardiomyopathy 2021 , 1, 144-146		

318	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.. <i>Circulation: Cardiovascular Interventions</i> , 2021 , CIRCINTERVENTIONS120010390	6	0
317	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.. <i>Lancet, The</i> , 2021 ,	40	34
316	Clinical Events Classification (CEC) in Clinical Trials: Report on the Current Landscape and Future Directions - Proceedings from the CEC Summit 2018.. <i>American Heart Journal</i> , 2021 , 246, 93-93	4.9	1
315	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021 ,	59.2	15
314	Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2021 ,	16.7	7
313	Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. <i>Circulation</i> , 2021 , 144, 1738-1746	16.7	6
312	Telemedicine for the treatment of foot ulcers in people with diabetes. <i>The Cochrane Library</i> , 2021 ,	5.2	78
311	Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 - AuthorsReply. <i>Lancet, The</i> , 2021 , 398, 1304	40	
310	Ultrasound guidance for arterial (other than femoral) catheterisation in adults. <i>The Cochrane Library</i> , 2021 , 10, CD013585	5.2	2
309	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2021 ,	14.6	2
308	The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e29-e30 ^{6.4}		
307	Evaluation of 1-Year Follow-up of Patients Included in the Registry of Clinical Practice in Patients at High Cardiovascular Risk (REACT). <i>Arquivos Brasileiros De Cardiologia</i> , 2021 , 116, 108-116	1.2	0
306	Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. <i>Circulation</i> , 2021 , 143, 790-804	16.7	21
305	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2021 , 143, 1215-1223	16.7	1
304	Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. <i>American Heart Journal</i> , 2021 , 233, 86-91	4.9	15
303	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021 , 14, e009614	6.4	1
302	Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. <i>Acta Cardiologica</i> , 2021 , 1-5	0.9	0
301	Renal denervation for the treatment of ventricular arrhythmias: A systematic review and meta-analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2021 , 32, 1430-1439	2.7	1

300	Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial". <i>Circulation</i> , 2021 , 143, e961-e962	16.7	
299	Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. <i>American Journal of Cardiology</i> , 2021 , 148, 69-77	3	2
298	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2021 , 397, 2253-2263	40	150
297	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <i>Circulation</i> , 2021 , 144, 74-84	16.7	9
296	The association between cardiac intensive care unit mechanical ventilation volumes and in-hospital mortality. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 797-805	4.3	1
295	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. <i>JAMA Network Open</i> , 2021 , 4, e2117963	10.4	0
294	Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial. <i>American Heart Journal</i> , 2021 , 231, 18-24	4.9	4
293	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 117-128	59.2	408
292	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021 , 384, 129-139	59.2	243
291	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators. <i>American Heart Journal</i>	4.9	2
290	Anticoagulation dosing in atherosclerotic cardiovascular disease: Is less more?. <i>European Journal of Internal Medicine</i> , 2021 , 83, 8-9	3.9	
289	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal: Quality of Care and Clinical Research</i> , 2021 , 7, 550-560	6.4	14
288	Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. <i>Heart</i> , 2021 , 107, 713-720	5.1	5
287	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021 , 5, e24-e34		6
286	Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2021 , 10, e016835	6	11
285	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 254-264	27.4	157
284	Galectin-3 Associated with Severe Forms and Long-term Mortality in Patients with Chagas Disease. <i>Arquivos Brasileiros De Cardiologia</i> , 2021 , 116, 248-256	1.2	2
283	Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention-Reply. <i>JAMA Cardiology</i> , 2021 , 6, 241	16.2	

282	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. <i>Circulation</i> , 2021 , 143, 583-596	16.7	31
281	Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement. <i>American Heart Journal</i> , 2021 , 233, 151-152	4.9	
280	Association of the left common ostium with clinical outcome after pulmonary vein isolation in atrial fibrillation. <i>Indian Pacing and Electrophysiology Journal</i> , 2021 , 21, 95-100	1.5	1
279	Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021 , 117, 181-264	1.2	7
278	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2021 ,	9.9	3
277	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. <i>Annals of Internal Medicine</i> , 2021 , 174, 1065-1072	8	6
276	Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTion cOroNavirus)-Coalition IV trial. <i>American Heart Journal</i> , 2021 , 238, 1-11	4.9	10
275	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2772-2780	15.4	0
274	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021 , 144, 1295-1307	16.7	13
273	Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. <i>Current Heart Failure Reports</i> , 2021 , 18, 253-263	2.8	1
272	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	14
271	Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021 , 117, 561-598	1.2	15
270	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 896-907	59.2	79
269	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 653-662	18.1	58
268	High risk coronavirus disease 2019: The primary results of the CoronaHeart multi-center cohort study. <i>IJC Heart and Vasculature</i> , 2021 , 36, 100853	2.4	
267	Medically Ill hospitalized Patients for COVID-19 THrombosis Extended PropyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. <i>American Heart Journal</i> , 2021 , 242, 115-122	4.9	10
266	Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. <i>Circulation</i> , 2021 , 143, 372-388	16.7	22
265	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. <i>BMJ, The</i> , 2021 , 372, n84	5.9	186

264	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , 2021 , e023143	6	
263	Chest Pain Network with Support of Telemedicine: Impact on Reperfusion Therapy and Clinical Outcomes After 8 Years of Experience. <i>Telemedicine Reports</i> , 2021 , 2, 284-292	2	
262	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e018984	6	9
261	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2297-2308	15.1	23
260	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. <i>American Heart Journal</i> , 2020 , 226, 49-59	4.9	87
259	Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?. <i>Current Hypertension Reports</i> , 2020 , 22, 43	4.7	23
258	Ultrasound guidance for arterial (other than femoral) catheterisation in adults. <i>The Cochrane Library</i> , 2020 ,	5.2	1
257	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2287-2295	15.4	5
256	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1145-1155	15.1	19
255	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. <i>Circulation</i> , 2020 , 141, 1618-1627	16.7	48
254	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020 , 141, 1384-1392	16.7	36
253	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 162-171	15.1	17
252	Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial. <i>American Heart Journal</i> , 2020 , 227, 100-106	4.9	10
251	A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2020 , 319, 85-93	3.2	3
250	Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029620936350	3.3	19
249	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. <i>JAMA Cardiology</i> , 2020 , 5, 582-589	16.2	34
248	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 242-257	14.8	41
247	Chagas disease: still a neglected emergency?. <i>Lancet, The</i> , 2020 , 395, 1113-1114	4.0	3

246	Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. <i>American Heart Journal</i> , 2020 , 226, 4-12	4.9	2
245	New Approaches to Conducting Randomized Controlled Trials. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 556-559	15.1	11
244	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	2
243	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 96, E102-E109	2.7	4
242	Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1311-1319	3.9	1
241	Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2020 , 221, 1-8	4.9	10
240	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020 , 141, 781-783	16.7	48
239	Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2020 , 302, 53-58	3.2	2
238	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020 , 43, 446-452	14.6	31
237	Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: A systematic review. <i>American Heart Journal</i> , 2020 , 229, 52-60	4.9	6
236	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020 , 41, 4037-4046	9.5	52
235	Consumer-led screening for atrial fibrillation using consumer-facing wearables, devices and apps: A survey of health care professionals by AF-SCREEN international collaboration. <i>European Journal of Internal Medicine</i> , 2020 , 82, 97-104	3.9	17
234	COVID-19 in Brazil: the headlines should be about science. <i>Lancet, The</i> , 2020 , 396, 1803	4.0	1
233	Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006550	5.8	2
232	Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e017024	6	13
231	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. <i>New England Journal of Medicine</i> , 2020 , 383, 2117-2126	59.2	67
230	The atrial Fibrillation real World management registry in the Middle East and Africa: design and rationale. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 704-710	1.9	2
229	Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial. <i>American Heart Journal</i> , 2020 , 228, 91-97	4.9	

228	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 2041-2052	59.2	620
227	Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 580-589	15.1	22
226	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. <i>Lancet, The</i> , 2020 , 396, 959-967	40	183
225	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial. <i>Circulation</i> , 2020 , 142, 1725-1735	16.7	27
224	Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020 , 3, e2015943	10.4	2
223	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 , 159, 2302-2309.e6	1.5	21
222	Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events. <i>Trials</i> , 2020 , 21, 323	2.8	3
221	Association Between Delays in Mechanical Ventilation Initiation and Mortality in Patients With Refractory Cardiogenic Shock. <i>JAMA Cardiology</i> , 2020 , 5, 965-967	16.2	9
220	High-quality evidence to inform clinical practice. <i>Lancet, The</i> , 2019 , 394, 633-634	40	5
219	Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). <i>American Journal of Cardiology</i> , 2019 , 124, 1406-1412	3	7
218	Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 615-623	3.9	25
217	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2019 , 140, 1921-1932	16.7	40
216	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2019 , 140, 1960-1963	16.7	6
215	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019 , 218, 57-65	4.9	3
214	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019 , 218, 110-122	4.9	7
213	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. <i>Circulation</i> , 2019 , 140, 1613-1622	16.7	26
212	Zika and Chikungunya Virus and Risk for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029618821184	3.3	34
211	Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619856433	3.3	2

210	Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS. <i>European Journal of Internal Medicine</i> , 2019 , 65, 4-5	3.9	4
209	Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2019 , 213, 57-65	4.9	6
208	Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. <i>International Journal of Cardiology</i> , 2019 , 289, 58-62	3.2	0
207	Effect of a Quality Improvement Intervention on Adherence to Therapies for Patients With Acute Ischemic Stroke and Transient Ischemic Attack: A Cluster Randomized Clinical Trial. <i>JAMA Neurology</i> , 2019 , 76, 932-941	17.2	9
206	International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 27-34	5.1	4
205	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019 , 380, 1509-1524	59.2	538
204	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. <i>Clinical Cardiology</i> , 2019 , 42, 568-571	3.3	43
203	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1069-1080	27.4	79
202	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 345-352	5.1	8
201	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019 , 4, 273-286	16.2	65
200	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007342	6	5
199	Prevalence of atrial fibrillation and stroke risk assessment based on telemedicine screening tools in a primary healthcare setting. <i>European Journal of Internal Medicine</i> , 2019 , 67, 36-41	3.9	12
198	Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2019 , 215, 106-113	4.9	5
197	Relation of Postdischarge Care Fragmentation and Outcomes in Transcatheter Aortic Valve Implantation from the STS/ACC TVT Registry. <i>American Journal of Cardiology</i> , 2019 , 124, 912-919	3	3
196	Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group. <i>International Journal of Cardiology</i> , 2019 , 296, 65-70	3.2	9
195	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 83-99	15.1	84
194	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 618-628	18.1	120
193	Development and validation of a questionnaire to assess the knowledge of mechanical ventilation in urgent care among students in their last-year medical course in Brazil. <i>Clinics</i> , 2019 , 74, e663	2.3	1

192	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019 , 139, 2292-2300	16.7	47
191	Peripheral blood metabolite profiles associated with new onset atrial fibrillation. <i>American Heart Journal</i> , 2019 , 211, 54-59	4.9	2
190	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. <i>Heart</i> , 2019 , 105, 235-242	5.1	11
189	Comparison of Outcomes and Frequency of Graft Failure With Use of Free Versus In Situ Internal Mammory Artery Bypass Conduits (from the PREVENT IV Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 571-575	3	4
188	Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2019 , 40, 1492-1500 ³¹	9.5	31
187	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019 , 139, 863-873	16.7	8
186	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019 , 208, 65-73	4.9	7
185	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2019 , 208, 123-131	4.9	35
184	Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. <i>Circulation</i> , 2019 , 139, 748-756	16.7	17
183	Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial. <i>American Heart Journal</i> , 2019 , 207, 40-48	4.9	1
182	Usefulness of Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2019 , 123, 12-18	3	10
181	Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. <i>American Journal of Cardiology</i> , 2019 , 123, 69-74	3	37
180	An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial. <i>American Heart Journal</i> , 2019 , 207, 49-57	4.9	7
179	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1063-1074	15.1	99
178	Stroke prevention in atrial fibrillation: re-defining Real-world data within the broader data universe. <i>European Heart Journal</i> , 2018 , 39, 2932-2941	9.5	19
177	Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery. <i>American Heart Journal</i> , 2018 , 199, 150-155	4.9	0
176	Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. <i>Heart</i> , 2018 , 104, 1292-1299	5.1	12
175	Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation?. <i>European Heart Journal</i> , 2018 , 39, 461-463	9.5	4

174	An open-Label, 2x2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , 2018 , 200, 17-23	4.9	56
173	Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 578-587	5.1	
172	Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 1331-1340	27.4	64
171	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 391-399	16.2	49
170	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2018 , 197, 1-8	4.9	5
169	Implementation of a Regional Network for ST-Segment-Elevation Myocardial Infarction (STEMI) Care and 30-Day Mortality in a Low- to Middle-Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). <i>Journal of the American Heart Association</i> , 2018 , 7,	6	16
168	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 721-733	15.1	21
167	Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2018 , 23, 523-530	3.3	18
166	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <i>American Heart Journal</i> , 2018 , 201, 25-32	4.9	6
165	Epicardial adipose tissue and carotid artery disease: Protocol for systematic review and meta-analysis. <i>Medicine (United States)</i> , 2018 , 97, e0273	1.8	2
164	The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 435-442	3.9	3
163	The high cost of critical care unit over-utilization for patients with NSTEMI ACS. <i>American Heart Journal</i> , 2018 , 202, 84-88	4.9	14
162	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018 , 270, 96-101	3.2	7
161	Coronary Artery Fistula Causing Acute Myocardial Infarction and Right Ventricle Thrombus. <i>Cureus</i> , 2018 , 10, e2314	1.2	1
160	Paradoxical Embolism in a Patient with Aortic Valve Endocarditis: A Case Report. <i>Cureus</i> , 2018 , 10, e2301	1.2	
159	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2018 , 197, 133-141	4.9	16
158	Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. <i>American Journal of Medicine</i> , 2018 , 131, 269-275.	2.4	60
157	Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018 , 27, 606-619	2.8	11

156	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. <i>Open Heart</i> , 2018 , 5, e000908	3	4
155	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004755	5.8	23
154	Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3274-3284	15.1	31
153	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , 2018 , 392, 1519-1529	40	771
152	The First Brazilian Registry of Hypertension. <i>American Heart Journal</i> , 2018 , 205, 154-157	4.9	6
151	Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. <i>American Journal of Medicine</i> , 2018 , 131, 1075-1085.e4	2.4	12
150	Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2018 , 138, 1402-1411	16.7	14
149	Usefulness and Cost-Effectiveness of Universal Echocardiographic Contrast to Detect Left Ventricular Thrombus in Patients with Heart Failure and Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2018 , 122, 121-128	3	2
148	Reply: Digoxin Use in Atrial Fibrillation: Minimizing and Refining its Use When Still Needed. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 125-126	15.1	
147	International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	4
146	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	25
145	Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. <i>Diabetes Care</i> , 2017 , 40, 73-80	4.9	14
144	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2017 , 185, 140-149	4.9	31
143	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017 , 186, 91-99	4.9	24
142	Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome. <i>Annals of Thoracic Surgery</i> , 2017 , 104, 98-105	2.7	6
141	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. <i>Heart</i> , 2017 , 103, 623-628	5.1	30
140	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. <i>American Journal of Medicine</i> , 2017 , 130, 1170-1176	2.4	6
139	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolic Events in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <i>American Heart Journal</i> , 2017 , 189, 137-145	4.9	170

138	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 295-301	3.9	2
137	Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	5
136	Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. <i>Clinical Cardiology</i> , 2017 , 40, 899-906	3.3	2
135	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 525-534	16.2	13
134	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. <i>Blood</i> , 2017 , 129, 2980-2987	2.2	70
133	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017 , 187, 194-203	4.9	15
132	Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 43, 446-453	5.1	2
131	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017 , 48, 3266-3273	6.7	13
130	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017 , 40, 1763-1770	14.6	46
129	Evaluation of self-perception of mechanical ventilation knowledge among Brazilian final-year medical students, residents and emergency physicians. <i>Clinics</i> , 2017 , 72, 65-70	2.3	9
128	Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 544-555	5.1	
127	Glycemic control in patients undergoing coronary artery bypass graft surgery: Clinical features, predictors, and outcomes. <i>Journal of Critical Care</i> , 2017 , 42, 328-333	4	6
126	Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	7
125	Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMPROVE treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). <i>American Heart Journal</i> , 2017 , 192, 38-47	4.9	3
124	Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. <i>American Journal of Medicine</i> , 2017 , 130, 1440-1448.e1	2.4	83
123	Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	15
122	Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2017 , 227, 443-449	3.2	2
121	Nonsteroidal Anti-Inflammatory Drugs and Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. <i>American Journal of Medicine</i> , 2017 , 130, 462-468	2.4	11

120	A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. <i>Lancet, The</i> , 2017 , 390, 1737-1746	40	106
119	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016 , 134, 1697-1707	16.7	58
118	Use of Direct Oral Anticoagulants in Special Populations. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 1053-71	3.1	3
117	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. <i>Diabetes Care</i> , 2016 , 39, 2304-2310	14.6	114
116	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 451-60	16.2	100
115	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 32-67	5.1	167
114	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Medicine</i> , 2016 , 129, 592-599.e1	2.4	40
113	Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. <i>Circulation</i> , 2016 , 133, 131-8	16.7	51
112	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1289-97	15.1	13
111	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016 , 102, 508-17	5.1	51
110	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016 , 175, 175-83	4.9	10
109	Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. <i>American Heart Journal</i> , 2016 , 174, 60-7	4.9	3
108	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 1582-90	9.5	235
107	Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. <i>American Heart Journal</i> , 2016 , 176, 10-6	4.9	5
106	Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes. <i>American Heart Journal</i> , 2016 , 173, 57-66	4.9	18
105	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet, The</i> , 2016 , 387, 349-356	40	87
104	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2016 , 202, 589-94	3.2	29
103	Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. <i>Brazilian Journal of Cardiovascular Surgery</i> , 2016 , 31, 106-14	1.1	3

102	Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis. <i>Blood</i> , 2016 , 128, 88-88	2.2	
101	Mechanical Ventilation and Clinical Outcomes in Patients with Acute Myocardial Infarction: A Retrospective Observational Study. <i>PLoS ONE</i> , 2016 , 11, e0151302	3.7	4
100	Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	1
99	A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. <i>American Heart Journal</i> , 2016 , 176, 107-13	4.9	7
98	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016 , 387, 2302-2311	4.0	272
97	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 126-35	16.2	161
96	The Obesity Paradox in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. <i>European Heart Journal</i> , 2016 , 37, 2869-2878	9.5	144
95	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016 , 133, 1560-73	16.7	15
94	First-Ever Stroke and Transient Ischemic Attack Incidence and 30-Day Case-Fatality Rates in a Population-Based Study in Argentina. <i>Stroke</i> , 2016 , 47, 1640-2	6.7	28
93	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016 , 129, S1-S29	2.4	19
92	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2016 , 177, 1-8	4.9	18
91	Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2016 , 178, 176-84	4.9	5
90	A time-series analysis of the relation between unemployment rate and hospital admission for acute myocardial infarction and stroke in Brazil over more than a decade. <i>International Journal of Cardiology</i> , 2016 , 224, 33-36	3.2	5
89	Letter by Hess et al Regarding Article, "How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoring". <i>Circulation</i> , 2016 , 134, e28-9	16.7	2
88	Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. <i>Clinical Cardiology</i> , 2016 , 39, 497-506	3.3	4
87	A Brazilian perspective for the use of bovine heparin in open heart surgery. <i>International Journal of Cardiology</i> , 2016 , 223, 611-612	3.2	6
86	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015 , 101, 1475-84	5.1	10
85	Response to letter regarding article, "surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience". <i>Circulation</i> , 2015 , 131, e378-9	16.7	1

84	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Circulation</i> , 2015 , 132, 624-32	16.7	159
83	Integrating electronic health records in the delivery of optimized anticoagulation therapy. <i>Annals of Pharmacotherapy</i> , 2015 , 49, 125-6	2.9	
82	Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 777-787	15.1	31
81	The Preservation and Handling of Vein Grafts in Current Surgical Practice: Findings of a Survey Among Cardiovascular Surgeons of Top-Ranked US Hospitals. <i>JAMA Surgery</i> , 2015 , 150, 681-3	5.4	9
80	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2015 , 169, 25-30	4.9	51
79	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial. <i>American Heart Journal</i> , 2015 , 169, 175-84	4.9	16
78	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015 , 36, 1264-72	9.5	99
77	Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. <i>American Journal of Medicine</i> , 2015 , 128, 297-302	2.4	6
76	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 86-94	6.4	44
75	Cumulative incidence of death and rehospitalization among the elderly in the first year after NSTEMI. <i>American Journal of Medicine</i> , 2015 , 128, 582-90	2.4	23
74	Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STRategic Reperfusion Early After Myocardial infarction trial. <i>American Heart Journal</i> , 2015 , 169, 890-898.e1	4.9	17
73	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	46
72	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015 , 36, 3268-75	9.5	30
71	Response to Letters Regarding Article, "Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IV". <i>Circulation</i> , 2015 , 132, e29	16.7	3
70	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. <i>American Heart Journal</i> , 2015 , 169, 531-8	4.9	6
69	The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. <i>American Heart Journal</i> , 2015 , 169, 315-22	4.9	8
68	Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. <i>Clinical Chemistry</i> , 2015 , 61, 368-78	5.5	29
67	Abstract 17277: Apixaban Use in Patients With Atrial Fibrillation With Bioprosthetic Valves: Insights From ARISTOTLE. <i>Circulation</i> , 2015 , 132,	16.7	11

66	Isolated Double Orifice Mitral Valve - a Rare Finding in an Elderly Man. <i>Arquivos Brasileiros De Cardiologia</i> , 2015 , 104, e53-4	1.2	
65	Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2144-2147	15.1	260
64	High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 52-61	15.1	114
63	Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1082-7	15.1	189
62	Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Circulation</i> , 2014 , 130, 1847-58	16.7	188
61	Reply: To PMID 24360877. <i>Annals of Thoracic Surgery</i> , 2014 , 98, 1890	2.7	
60	Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. <i>Europace</i> , 2014 , 16, 1284-90	3.9	6
59	Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial. <i>International Journal of Cardiology</i> , 2014 , 176, 1126-8	3.2	8
58	Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. <i>Circulation</i> , 2014 , 130, 1445-51	16.7	138
57	Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1541-50	15.1	67
56	Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STRategic Reperfusion Early After Myocardial Infarction [STREAM] study). <i>American Journal of Cardiology</i> , 2014 , 114, 811-9	3	22
55	Response to the Letter to the Editor titled "Atrial fibrillation in patients with acute coronary syndromes". <i>International Journal of Cardiology</i> , 2014 , 171, e106	3.2	
54	Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery. <i>Annals of Thoracic Surgery</i> , 2014 , 97, 824-30	2.7	10
53	Surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience. <i>Circulation</i> , 2014 , 129, 2547-56	16.7	70
52	Central venous pressure after coronary artery bypass surgery: does it predict postoperative mortality or renal failure?. <i>Journal of Critical Care</i> , 2014 , 29, 1006-10	4	39
51	Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>American Heart Journal</i> , 2014 , 168, 303-9	4.9	101
50	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. <i>Blood</i> , 2014 , 124, 3692-8	2.2	124
49	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014 , 35, 1864-72	9.5	237

48	Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review. <i>International Journal of Cardiology</i> , 2014 , 177, 990-4	3.2	13
47	Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. <i>JAMA Surgery</i> , 2014 , 149, 798-805	5.4	52
46	Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry. <i>American Heart Journal</i> , 2014 , 168, 213-9.e1	4.9	44
45	Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 37, 331-7	5.1	4
44	An evaluation of the professional, social and demographic profile and quality of life of physicians working at the Prehospital Emergency Medical System (SAMU) in Brazil. <i>Clinics</i> , 2014 , 69, 601-7	2.3	9
43	Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. <i>Trials</i> , 2013 , 14, 123	2.8	17
42	Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 36, 115-30	5.1	
41	Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. <i>American Heart Journal</i> , 2013 , 166, 208-216.e28	4.9	19
40	Results of a reevaluation of cardiovascular outcomes in the RECORD trial. <i>American Heart Journal</i> , 2013 , 166, 240-249.e1	4.9	128
39	Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1461-3	15.1	1
38	Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2013 , 165, 918-925.e2	4.9	63
37	Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. <i>International Journal of Cardiology</i> , 2013 , 167, 2580-7	3.2	11
36	Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2013 , 166, 549-58	4.9	35
35	Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013 , 168, 2510-7	3.2	14
34	Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. <i>JACC: Heart Failure</i> , 2013 , 1, 223-9	7.9	29
33	Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. <i>Circulation</i> , 2013 , 127, 2166-76	16.7	164
32	Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. <i>Postgraduate Medicine</i> , 2013 , 125, 146-57	3.7	
31	Ankle-brachial index as a predictor of coronary disease events in elderly patients submitted to coronary angiography. <i>Clinics</i> , 2013 , 68, 1481-7	2.3	12

30	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 1749-58	40	150
29	Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. <i>American Heart Journal</i> , 2012 , 164, 607-15	4.9	20
28	Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 552-61	5.1	7
27	Heart Failure Survival Score in Patients With Chagas Disease: Correlation With Functional Variables. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 538-543	0.7	
26	Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. <i>American Journal of Medicine</i> , 2012 , 125, 897-905	2.4	26
25	Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. <i>Circulation</i> , 2012 , 125, 2914-21	16.7	92
24	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 143-63	5.1	
23	Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. <i>Circulation</i> , 2012 , 125, 749-56	16.7	98
22	The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2012 , 33, 2044-53	9.5	61
21	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856
20	Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. <i>Blood</i> , 2011 , 118, 6269-73	2.2	27
19	Diagnosing acute myocardial infarction in patients with left bundle branch block. <i>American Journal of Cardiology</i> , 2011 , 108, 782-8	3	35
18	Antiplatelet agents in cardiovascular disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 31, 306-9	5.1	14
17	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, SB Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 32, 242-66	5.1	2
16	In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding. <i>Evidence-Based Medicine</i> , 2011 , 16, 187-8		
15	Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. <i>Stroke</i> , 2011 , 42, 3477-83	6.7	28
14	Usefulness of Extended-FAST (EFAST-Extended Focused Assessment with Sonography for Trauma) in critical care setting. <i>Revista Brasileira De Terapia Intensiva</i> , 2010 , 22, 291-9	1.2	11
13	Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. <i>American Heart Journal</i> , 2010 , 159, 331-9	4.9	345

12	Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. <i>American Journal of Medicine</i> , 2010 , 123, 134-40	2.4	35
11	Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 669-77	5	16
10	Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. <i>European Heart Journal</i> , 2009 , 30, 2019-28	9.5	111
9	Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. <i>New England Journal of Medicine</i> , 2009 , 361, 235-44	59.2	264
8	Antiplatelet therapy in older adults with non-ST-segment elevation acute coronary syndrome: considering risks and benefits. <i>American Journal of Cardiology</i> , 2009 , 104, 16C-21C	3	15
7	Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). <i>American Journal of Cardiology</i> , 2009 , 104, 1285-91	3	7
6	Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 28, 106-16	5.1	1
5	Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1021-30	15.1	106
4	Late-breaking trials summary from the 2008 American College of Cardiology Scientific Sessions, March 29 to April 1, Chicago, IL. <i>American Heart Journal</i> , 2008 , 156, 7-12	4.9	2
3	Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. <i>European Heart Journal</i> , 2008 , 29, 1827-33	9.5	32
2	Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 26, 167-74	5.1	11
1	Novel Markers in Patients with Suspected Acute Coronary Syndromes75-92		